SCHEMBL3206725

SCHEMBL3206725

CCCC[n+]1ccc(-c2cc[n+](C)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.69
TP53 P04637 1/20 0.69
CYP1A2 P05177 1/20 0.69
CYP2D6 P10635 1/20 0.69
MAPT P10636 1/20 0.69
CYP2C9 P11712 1/20 0.69
CYP2C19 P33261 1/20 0.69
KMT2A Q03164 1/20 0.69
HTT P42858 2/20 0.67
KDM4E B2RXH2 1/20 0.67
NPC1 O15118 1/20 0.67
LMNA P02545 1/20 0.67
RAB9A P51151 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
SLC6A4 P31645 2/20 0.48
SLC22A2 O15244 1/20 0.48
SLC22A1 O15245 1/20 0.48
SLC22A3 O75751 1/20 0.48
ABCB11 O95342 1/20 0.43
ESR1 P03372 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3210926 0.94 KMT2A (0.80) MEN1TP53CYP1A2CYP2D6MAPT
SCHEMBL3198349 0.92 KMT2A (0.84) MEN1TP53CYP1A2CYP2D6MAPT
SCHEMBL3217580 0.92 KMT2A (0.84) MEN1TP53CYP1A2CYP2D6MAPT
SCHEMBL3206447 0.92 KMT2A (0.84) MEN1TP53CYP1A2CYP2D6MAPT
SCHEMBL3215274 0.92 KMT2A (0.84) MEN1TP53CYP1A2CYP2D6MAPT
SCHEMBL3217713 0.92 KMT2A (0.84) MEN1TP53CYP1A2CYP2D6MAPT
SCHEMBL3218482 0.92 KMT2A (0.84) MEN1TP53CYP1A2CYP2D6MAPT
SCHEMBL13928786 0.92 KMT2A (0.84) MEN1TP53CYP1A2CYP2D6MAPT
SCHEMBL21777162 0.92 KMT2A (0.84) MEN1TP53CYP1A2CYP2D6MAPT
SCHEMBL19618006 0.92 KMT2A (0.84) MEN1TP53CYP1A2CYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119585421-A Enzyme electrode, enzyme reaction device, enzyme reaction method, modified protein, and method for producing modified protein 松下知识产权经营株式会社 2025-03-07 CN disclosed
CN-119585422-A Enzyme electrode, reduction device, reduction method, modified protein, and method for producing modified protein 松下知识产权经营株式会社 2025-03-07 CN disclosed
US-20230192692-A1 MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF TIANJIN NORMAL UNIVERSITY (CN) 2023-06-22 US disclosed
EP-4169932-A1 METHOD FOR CLEAVING DISULFIDE BOND IN PROTEIN AND DEVICE FOR CLEAVING DISULFIDE BOND IN PROTEIN Panasonic Intellectual Property Management Co., Ltd. (JP) 2023-04-26 EP disclosed
US-20230117095-A1 TARGET MOLECULE REDOX METHOD AND TARGET MOLECULE REDOX DEVICE PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2023-04-20 US disclosed
CN-115916798-A Method and apparatus for cleaving disulfide bond in protein 松下知识产权经营株式会社 2023-04-04 CN disclosed
CN-115702344-A Target molecule redox method and target molecule redox device 松下知识产权经营株式会社 2023-02-14 CN disclosed
US-11215935-B2 Electrophotographic photoreceptor, process cartridge, and image forming apparatus FUJIFILM BUSINESS INNOVATION CORP. (JP) 2022-01-04 US disclosed
US-11169455-B2 Electrophotographic photoreceptor, process cartridge, and image forming apparatus FUJIFILM BUSINESS INNOVATION CORP. (JP) 2021-11-09 US disclosed
US-20200341392-A1 ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS FUJI XEROX CO., LTD. (JP) 2020-10-29 US disclosed
US-9190695-B2 Nonaqueous electrolyte solution, method for producing same, and nonaqueous electrolyte battery using the electrolyte solution WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2015-11-17 US disclosed
EP-2602855-B1 NONAQUEOUS ELECTROLYTE SOLUTION, METHOD FOR PRODUCING SAME, AND NONAQUEOUS ELECTROLYTE BATTERY USING THE ELECTROLYTE SOLUTION WAKO PURE CHEM IND LTD (JP) 2015-02-18 EP disclosed
US-20140212459-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH (DE) 2014-07-31 US disclosed
EP-2602856-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME Wako Pure Chemical Industries, Ltd. (JP) 2013-06-12 EP disclosed
EP-2602855-A1 NONAQUEOUS ELECTROLYTE SOLUTION, METHOD FOR PRODUCING SAME, AND NONAQUEOUS ELECTROLYTE BATTERY USING THE ELECTROLYTE SOLUTION Wako Pure Chemical Industries, Ltd. (JP) 2013-06-12 EP disclosed
US-20130143129-A1 NONAQUEOUS ELECTROLYTE SOLUTION, METHOD FOR PRODUCING SAME, AND NONAQUEOUS ELECTROLYTE BATTERY USING THE ELECTROLYTE SOLUTION WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2013-06-06 US disclosed
US-20130130128-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2013-05-23 US disclosed
US-8269038-B2 Process for production of sulfonic acid ester WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-09-18 US disclosed
US-20100041916-A1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-02-18 US disclosed
EP-2067770-A1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER Wako Pure Chemical Industries, Ltd. (JP) 2009-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041916-A1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER SULT1A1, SULT2A1, STS MEN1 3623/4885TP53 4469/4885CYP1A2 337/4885
US-20140212459-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF DHPS, DOHH, PAH MEN1 1722/4885TP53 3520/4885CYP1A2 325/4885
US-20230192692-A1 MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF TPMT, NUDT1, PNP MEN1 4771/4885TP53 180/4885CYP1A2 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.